NHS Valuation

Neuberger Berman High Yield Strategies Fund (NHS) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Neuberger Berman High Yield Strategies Fund (NHS) is between -- to -- according to relative valuation method.

NHS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Neuberger Berman High Yield Strategies Fund (NHS) is between -- to -- according to relative valuation method.

The average P/S ratio for NHS's competitors is 0.00, providing a benchmark for relative valuation. Neuberger Berman High Yield Strategies Fund Corp (NHS) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

As of Mar 04 2026, Neuberger Berman High Yield Strategies Fund (NHS) has a P/B ratio of NaN. This indicates that the market values NHS at NaN times its book value.

As of Mar 04 2026, Neuberger Berman High Yield Strategies Fund (NHS) has a FCF Yield of NaN%. This means that for every dollar of Neuberger Berman High Yield Strategies Fund's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 04 2026, Neuberger Berman High Yield Strategies Fund (NHS) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Neuberger Berman High Yield Strategies Fund's expected earnings over the next 12 months.

As of Mar 04 2026, Neuberger Berman High Yield Strategies Fund (NHS) has a Forward P/S ratio of NaN. This means the market is valuing NHS at $NaN for every dollar of expected revenue over the next 12 months.